CA2557174C - Procede de purificaton d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant - Google Patents
Procede de purificaton d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant Download PDFInfo
- Publication number
- CA2557174C CA2557174C CA2557174A CA2557174A CA2557174C CA 2557174 C CA2557174 C CA 2557174C CA 2557174 A CA2557174 A CA 2557174A CA 2557174 A CA2557174 A CA 2557174A CA 2557174 C CA2557174 C CA 2557174C
- Authority
- CA
- Canada
- Prior art keywords
- albumin
- solution
- aqueous
- nanofiltration
- solutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001728 nano-filtration Methods 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 16
- 238000000746 purification Methods 0.000 title claims abstract description 12
- 108010088751 Albumins Proteins 0.000 claims abstract description 138
- 102000009027 Albumins Human genes 0.000 claims abstract description 137
- 239000000243 solution Substances 0.000 claims abstract description 109
- 239000007864 aqueous solution Substances 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000006978 adaptation Effects 0.000 claims abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 239000011780 sodium chloride Substances 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000006641 stabilisation Effects 0.000 claims description 5
- 238000011105 stabilization Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 3
- 102100036537 von Willebrand factor Human genes 0.000 claims description 3
- 229960001134 von willebrand factor Drugs 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 150000001340 alkali metals Chemical group 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 230000004720 fertilization Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 210000000287 oocyte Anatomy 0.000 claims description 2
- 239000000813 peptide hormone Substances 0.000 claims description 2
- 239000004627 regenerated cellulose Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229940043517 specific immunoglobulins Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 238000001914 filtration Methods 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 26
- 230000003612 virological effect Effects 0.000 description 17
- 101710153593 Albumin A Proteins 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 10
- 229960003529 diazepam Drugs 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 238000009928 pasteurization Methods 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229960005080 warfarin Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- -1 NaOH and KOH Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001595 flow curve Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 229960005480 sodium caprylate Drugs 0.000 description 3
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010074864 Factor XI Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000309711 non-enveloped viruses Species 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710153591 Albumin B Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- RJNYIELPXWUWPG-FVGYRXGTSA-M sodium;(2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound [Na+].C1=CC=C2C(C[C@H](N)C([O-])=O)=CNC2=C1 RJNYIELPXWUWPG-FVGYRXGTSA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003017 thermal stabilizer Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0402001 | 2004-02-27 | ||
| FR0402001A FR2866890B1 (fr) | 2004-02-27 | 2004-02-27 | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
| PCT/FR2005/000416 WO2005090402A1 (fr) | 2004-02-27 | 2005-02-23 | Procede de purificaton d’albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2557174A1 CA2557174A1 (fr) | 2005-09-29 |
| CA2557174C true CA2557174C (fr) | 2013-04-30 |
Family
ID=34834103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2557174A Expired - Lifetime CA2557174C (fr) | 2004-02-27 | 2005-02-23 | Procede de purificaton d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20070161122A1 (https=) |
| EP (1) | EP1718673B1 (https=) |
| JP (2) | JP4979571B2 (https=) |
| AT (1) | ATE373014T1 (https=) |
| AU (1) | AU2005223418B2 (https=) |
| BR (1) | BRPI0507886A (https=) |
| CA (1) | CA2557174C (https=) |
| CY (1) | CY1107082T1 (https=) |
| DE (1) | DE602005002461T2 (https=) |
| DK (1) | DK1718673T3 (https=) |
| ES (1) | ES2294696T3 (https=) |
| FR (1) | FR2866890B1 (https=) |
| IL (1) | IL177286A (https=) |
| PL (1) | PL1718673T3 (https=) |
| PT (1) | PT1718673E (https=) |
| WO (1) | WO2005090402A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2866890B1 (fr) * | 2004-02-27 | 2008-04-04 | Lab Francais Du Fractionnement | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
| FR2887883B1 (fr) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
| FR2894831B1 (fr) | 2005-12-16 | 2008-02-15 | Lab Francais Du Fractionnement | Colle biologique exempte de thrombine et son utilisation comme medicament. |
| ES2294976B1 (es) * | 2007-11-12 | 2008-12-16 | Grifols, S.A. | "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion". |
| KR20140093603A (ko) | 2010-12-30 | 2014-07-28 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 병원체 불활성화제로서의 글리콜 |
| FR3004451B1 (fr) * | 2013-04-11 | 2015-12-11 | Lab Francais Du Fractionnement | Procede de preparation d'une solution de proteine c viralement securisee par une double etape de nanofiltration |
| US20180028593A1 (en) * | 2014-03-21 | 2018-02-01 | Boreal Invest | Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates |
| FR3040882A1 (fr) * | 2015-09-10 | 2017-03-17 | Lab Francais Du Fractionnement | Composition liquide d'albumine humaine a usage therapeutique |
| WO2021155142A1 (en) * | 2020-01-30 | 2021-08-05 | Fresenius Medical Care Holdings, Inc. | Techniques for modelling and optimizing dialysis toxin displacer compounds |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| US12161777B2 (en) | 2020-07-02 | 2024-12-10 | Davol Inc. | Flowable hemostatic suspension |
| EP4267210A1 (en) | 2020-12-28 | 2023-11-01 | Davol Inc. | Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019919D0 (en) | 1990-09-12 | 1990-10-24 | Delta Biotechnology Ltd | Purification of proteins |
| FR2672604B1 (fr) * | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue. |
| US5849874A (en) * | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| US5440018A (en) | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| JPH06279296A (ja) * | 1993-03-25 | 1994-10-04 | Asahi Chem Ind Co Ltd | 血漿分画製剤中から蛋白質会合物の除去方法 |
| SE9500724D0 (sv) * | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
| DE60121196T2 (de) * | 2000-10-24 | 2007-07-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Verfahren zur monomerisierung von humanen serumalbumin-polymeren |
| US6806355B2 (en) * | 2001-08-14 | 2004-10-19 | Statens Serum Institut | Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product |
| DE10211632A1 (de) * | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| AU2004228847B2 (en) * | 2003-04-09 | 2010-06-17 | Km Biologics Co., Ltd. | Process for producing albumin preparation |
| FR2866890B1 (fr) * | 2004-02-27 | 2008-04-04 | Lab Francais Du Fractionnement | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
-
2004
- 2004-02-27 FR FR0402001A patent/FR2866890B1/fr not_active Expired - Lifetime
-
2005
- 2005-02-23 ES ES05731028T patent/ES2294696T3/es not_active Expired - Lifetime
- 2005-02-23 CA CA2557174A patent/CA2557174C/fr not_active Expired - Lifetime
- 2005-02-23 JP JP2007500249A patent/JP4979571B2/ja not_active Expired - Fee Related
- 2005-02-23 DK DK05731028T patent/DK1718673T3/da active
- 2005-02-23 PT PT05731028T patent/PT1718673E/pt unknown
- 2005-02-23 US US10/589,825 patent/US20070161122A1/en not_active Abandoned
- 2005-02-23 PL PL05731028T patent/PL1718673T3/pl unknown
- 2005-02-23 EP EP05731028A patent/EP1718673B1/fr not_active Expired - Lifetime
- 2005-02-23 AU AU2005223418A patent/AU2005223418B2/en not_active Ceased
- 2005-02-23 WO PCT/FR2005/000416 patent/WO2005090402A1/fr not_active Ceased
- 2005-02-23 DE DE602005002461T patent/DE602005002461T2/de not_active Expired - Lifetime
- 2005-02-23 BR BRPI0507886-5A patent/BRPI0507886A/pt active Search and Examination
- 2005-02-23 AT AT05731028T patent/ATE373014T1/de active
-
2006
- 2006-08-03 IL IL177286A patent/IL177286A/en not_active IP Right Cessation
-
2007
- 2007-12-12 CY CY20071101575T patent/CY1107082T1/el unknown
-
2011
- 2011-12-21 JP JP2011280288A patent/JP2012102115A/ja active Pending
-
2015
- 2015-02-02 US US14/611,460 patent/US9611311B2/en not_active Expired - Lifetime
-
2017
- 2017-02-27 US US15/443,884 patent/US10562957B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2557174A1 (fr) | 2005-09-29 |
| BRPI0507886A (pt) | 2007-08-07 |
| EP1718673A1 (fr) | 2006-11-08 |
| AU2005223418B2 (en) | 2008-12-18 |
| JP2007535495A (ja) | 2007-12-06 |
| US10562957B2 (en) | 2020-02-18 |
| PL1718673T3 (pl) | 2008-03-31 |
| IL177286A0 (en) | 2006-12-10 |
| EP1718673B1 (fr) | 2007-09-12 |
| DK1718673T3 (da) | 2008-01-14 |
| ES2294696T3 (es) | 2008-04-01 |
| US20070161122A1 (en) | 2007-07-12 |
| FR2866890B1 (fr) | 2008-04-04 |
| AU2005223418A1 (en) | 2005-09-29 |
| DE602005002461T2 (de) | 2008-06-12 |
| CY1107082T1 (el) | 2012-10-24 |
| ATE373014T1 (de) | 2007-09-15 |
| DE602005002461D1 (de) | 2007-10-25 |
| FR2866890A1 (fr) | 2005-09-02 |
| US20170166626A1 (en) | 2017-06-15 |
| JP4979571B2 (ja) | 2012-07-18 |
| US9611311B2 (en) | 2017-04-04 |
| WO2005090402A1 (fr) | 2005-09-29 |
| IL177286A (en) | 2012-08-30 |
| JP2012102115A (ja) | 2012-05-31 |
| US20150152162A1 (en) | 2015-06-04 |
| PT1718673E (pt) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2557174C (fr) | Procede de purificaton d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant | |
| BE1004178A3 (fr) | Procede de preparation a l'echelle industrielle d'un concentre de facteur von willebrand humain standardise, de tres haute purete, approprie a un usage therapeutique. | |
| EP1968634B1 (fr) | PROCÉDÉ DE PRÉPARATION DE CONCENTRE D' IMMUNOGLOBULINES G (IgG) APPAUVRI EN ANTICORPS ANTI-A ET ANTI-B | |
| FR2492270A2 (fr) | Appareil d'electrodialyse et procede de fractionnement de melanges de proteines | |
| CA2697404A1 (fr) | Procede de purification du facteur viii et du facteur von willebrand | |
| CA2314610C (fr) | Procede de preparation par filtration d'une solution de facteur viii securisee viralement | |
| EP3459552A1 (fr) | Procédé de preparation de plasma universel | |
| EP0683791B1 (fr) | Composition aqueuse proteinique, glycoproteine contenue, procede d'obtention et utilisations | |
| EP1632501B1 (fr) | Procédé de préparation d'un concentré de facteur von Willebrand (FvW) par voie chromatographique et concentré de FvW susceptible d'être ainsi obtenu | |
| EP3277703A1 (fr) | Procédé de purification d'une protéine recombinante thérapeutique à partir d'un lait transgénique | |
| FR3061020A1 (fr) | Composition de fibrinogene humain | |
| EP0888131B1 (fr) | Procede pour eliminer les agents transmissibles non conventionnels d'une solution proteique | |
| EP3897692A1 (fr) | Procédé de filtration du fibrinogène | |
| FR3076294A1 (fr) | Procede de purification d'anticorps a partir de lait brut | |
| EP0215081A1 (fr) | Preparations d'immunoglobulines presentant des titres eleves en anticorps bloquants | |
| FR3045387A1 (fr) | Composition d’immunoglobulines humaines concentrees |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |